Last reviewed · How we verify
NCT06834412
A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging
NA trial testing 68Ga-Pentixafor and 18F-FDG PET/CT Scan in Hematological Malignancies in 120 participants. Currently enrolling.
1 June 2025
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 120 |
| Start date | 3 November 2021 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-Pentixafor and 18F-FDG PET/CT Scan
Conditions studied
- Hematological Malignancies — all drugs for Hematological Malignancies →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 75, any sex, with Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, open-label, single-center clinical study targeting hematological malignancies. 120 patients with a confirmed by pathology of non-Hodgkin's lymphoma or myeloma were included. Qualified subjects will undergo 18F-FDG PET/CT and 68Ga-Pentixafor PET/CT examination. The aim is to To investigate whether 68Ga-pentixafor PET imaging can be used as a reliable complement to 18F-FDG PET imaging for clinical staging, treatment response evaluation, and re-staging of patients with hematological malignancies.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?
Hartrampf PE, Werner RA, Higuchi T, Schottelius M, et al · · 2026 · PMID 41819832 · DOI 10.2967/jnumed.125.271153 -
Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin's lymphoma.
Yu X, Tang H, Ou H, Quan Z, et al · · 2025 · PMID 41455028 · DOI 10.1186/s13550-025-01368-7
Verify or expand the search:
- PubMed search for NCT06834412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematological Malignancies
Currently open trials in the same condition.
- NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT06584955 — Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies · NA · active not recruiting
- NCT06387082 — A Clinical Study of HMPL-506 in Patients With Hematological Malignancies · Phase 1 · recruiting
- NCT06150469 — Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies · NA · recruiting
- NCT06179511 — Study of AZD9829 in CD123+ Hematological Malignancies · Phase 1, PHASE2 · active not recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06834412 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06834412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing